Member Info for cadburyhill

More likely to be bought by someone like Roche than go public. Public markets are going out of fashion for big technology 'unicorns' like this one...they prefer to fund privately from a few patient investors than have to be buffeted about in cowboy public markets. But I'm sure the work has been done and the IPO route can happen if there is a massively improved change in market sentiment. I guess it would be Nasdaq listed if it ever did happen... IPO LN now trading at its net asset value....a great entry point in my view. Oxford Nano, TRX, XEROS, Actual Experience, Ceres, etc etc etc. The market has misjudged the maturity of these and other IP Group portfolio assets. After more than a decade of support, these companies are just about to see their top line grow exponentially....

It's an excellent company.... But it does consume cash. Your answer is in the balance sheet....market seems to be pricing in a cap raise.

nah, it's a declaration associated with that placing....still, quite interesting... not a 'proper' institution but not bad....parkwalk do lots of EIS/tax-related investing for wealthy individuals and family offices...

Amused. How a top 5 holder buying more of SYN y'day can be a bad thing, I do not know, Jolly! Griffiths doesn't get them all right - no-one does in this space. But he's pretty damned good. He flogged his tissue regenix stake to Woodford and banked £23mn in 2015... If Griffiths is buying more, then he has a reason and that's encouraging. There's no other way to look at it. I'm not even going to write 'in my view' to sign off. All best

can't claim that today is a good day but let's focus on fundamentals...1. the scientific / therapeutic thesis is still intact. we have had a trial design/recruitment issue not a fundamental issue to do with safety or efficacy. It's right that the stock should be marked down to reflect the additional discounting of future possible cashflows from this product line but it's wrong to think it ultimately less valuable/exciting. 2. we will have second-line data in early 2017 which may well be very useful with respect to this trial but others, too. 3. i'd prefer AZN to have done the right thing now rather than plough on with a mis-specified trial. Today's announcement is just part of the rub when trying to do clinical trials on difficult to treat patients. It's quite possible/probable? that AZN will be back with a new trial design shortly. 4. these guys have other therapeutic targets and i'm constantly impressed with their low cash burn and their lack of fuss / drama. The team here are really, really good scientists. By hanging onto SNG, you're owning a slice of these guys. 5. we have no funding risks near term. 6. the share register is of such high quality that none of them are going to dump on you. 7. there's always the chance that it gets taken over and its science/scientists incorporated within another larger player. Sure, we've probably all got to put it away in the bottom draw for a while now. But it still offers an upside profile which is utterly uncorrelated with macro noise like brexit and it has a place in a portfolio.

life is too short for me to fill up this chat with all the reasons why, but this stock is simply the wrong price around 30p. have a look at the quality of the board - ex-CFO of GSK, ex head at Kraft. this company has more polymer chemists than any of the big guys and they're winning contracts and divesting non-core. I think it's a fantastic story.

I think a cap raise is off table till back-end of 17. no-one would support a raise anywhere near current share price, even if they wanted to raise - which they do not. So, all focus is on operational developments and top line, with gibraltar as the icing on cake - if it gets sign-off (perhaps autumn budget statement and a bit of fiscal stimulus will do the trick?). I agree that there has been real progress here. the way the company now manages its cash/resources is outstanding...We just need some sense of momentum building via news from India, Middle East and a pick back up of sales in monitoring to instil confidence.

for us? given that the first tranches of cash from any realisation go to the brook macdonald people, under the agreed terms, i think we might start to see value realisations that benefit us in h2 2017/h1 2018. BUT the NAV will be marked up ahead of that from current utterly depressed level. So, I hope we move back towards 10p earlier in 2017. Things could go wrong - we need the macro to stay in tact - but we could also be +vely surprised by a particular juicy realisation price or some positive news out of mongolia (where things have been very difficult). the gearing of marginal assets like kincora to movements in sentiment and commodity prices is huge. hence things can happen very very quickly in terms of share price with a portfolio of assets like Origo's. good luck!

Yep, good China data this week, good move by copper price, court resolution / settlement a done deal but a catalyst which makes it investable / more investable to institutional guys...lots of progress across the portfolio to look forward to...( see full year15' RNS). It should mark up to 4p before ANY debate begins over longer term value etc.

seen the latest RNS? that's the second manager out of the way and material reduction in costs achieved. it's worth looking through the accounts to see how much they have been paying themselves. the ex-CEO was paid £500,000 give or take for 2015. Incredible....

seen the latest RNS? that's the second manager out of the way and material reduction in costs achieved. it's worth looking through the accounts to see how much they have been paying themselves. the ex-CEO was paid £500,000 give or take for 2015. Incredible....

"Oxford and Newcastle, UK - 9 September 2016 - e-Therapeutics plc (AIM: ETX), the drug discovery company, will announce its half year results for the six months ended 31 July 2016 on Tuesday,� 20 September 2016." yep, 20th Sept it is....we don't know what to expect over the next few quarters...all i know is that it's effectively trading at its cash with zero value for the intellectual property/science. so this is a valuation/mean-reversion trade. As private investors, we can't assess the value of the science but we hope the market has temporarily mispriced it, and that current institutional holders are doing their best to correct this misvaluation via management changes etc....good luck.

don't disagree with any of that, Jolly.... but i've got to be invested somewhere (i KNOW i can't time the market) and OCN is better than most, in my view....but do agree. Helicopter money should come in form of a fiscal stimulus - a 'New Deal' but let's see if the politicians bottle it, as they have done before. It clearly doesn't work to leave the central bankers to do all the work...

clearly we're at start? of a general market wobble - volatility can't stay low for ever and it's that time of year...if there's a rate rise issue, then that's pro-growth and i expect oil price to do fine and OCN to be underpinned. OCN is a 'real-asset' play with a very good yield and still 30% odd below my cautious NAV. you might be right and the stock fall back 5-10% given how illiquid it is and how overdue we are for a general market correction. But i'm not a trader and this company still works for me until we're up around 1250-1300p.all best.

Hi, bbr391. based on the utterly depressed NAV at last results and on the Brooks Macdonald deal structure, I thought 5p / 6p was a solid, unexciting and utterly realistic interim target for the market to move to. Kincora's copper asset (in which Origo converted a loan into more equity earlier in the year) is a big delta for the share price as the year progresses into 2017. Mongolian politics couldn't get much worse but in emerging markets 'the darkest hour is always before the dawn'. Although it's right to keep expectations low, the potential at Kincora alone is worth exposure to OPP, in my view.

So, we resume trading today. Fantastic progress. Well worth seeing what assets you get exposure to if you buy this share down here by reading the results RNS posted in July.

I reckon today's RNS is about as good as any ordinary shareholder could have wished for....Today, I read through the full results release in early July, paying more attention to the asset by asset descriptions than i did on the day when all i cared about was court proceedings (a read of the results RNS is well worth 10mins of anybody's time, by the way). I don't see any reason why this can't get back to 5p when trading resumes...It may go back towards 10p now we have finally resolved the Brooke Macdonald farce. There are some really interesting assets in here - somewhere. Excellent news for a friday. I'd written this off completely....The black sheep returning to the fold is always the most appreciated....

i wanted to bring the focus back on to battery tech so thank you to both Botak and Leonsix for helping me achieve that. My point was only that IKA will be defined by its success in battery tech / IOT and not by the odd grant win. Trading volumes have been low - I know this is summer - which suggests a bit of PI enthusiasm has accounted for this small spike and nothing more meaningful. Whether the share price goes up or down 10% on low volumes because of few PA punters have got religion, really doesn't mean anything at all in the long run. As Botak points out, we need to see institutional or strategic investors to really give us the confidence that we've finally got something globally disruptive / relevant. As a betting man, i suspect that the semi-conductor company is more likely to be someone like STM rather than ARM but that's a positive. A chip maker is ultimately more relevant than a chip designer, although I think we all expect ARM to be relevant at some point too, via the Chairman. By the way, I do like the Chairman. he gives a degree of commerciality to IKA that it has not had before. On the cash-burn side of things, note that we were at £3mn of cash back at time of launch of Stereax. In theory, that's one year from late spring 2016 but the cash-burn has surely increased (for the best of reasons). If we're pushing towards launch of other products in 2017 and there's increased marketing/cash spend around Stereax, I'd suggest that these guys need to come to market sooner rather than later, i.e. before December. We all hope they will do so with a licence agreement as the hook. Good luck!

Am a big fan of IKA and a long term investor, but the grant / collaboration with J-M just doesn't move the needle, so please be careful. We really need commercial agreement/licence deal for Stereax - asap. We're running out of cash and we need some industrial validation of our tech to justify a cap raise. IKA's history is full of grant wins like this. It's greatest weakness is that it gets used as a cheap outsourced R&D department by global players like toyota, RR, J-M. These guys throw a few hundred thousand pounds to IKA to say 'thanks' and buy the scientists a slap up dinner too, I presume. But it really doesn't change the price of anything and it certainly doesn't build the business into an independent, profitable entity.

good to read of UK treasury infrastructure project guarantees post Brexit (see front page of The Times, etc today). This should mean that any delay in confirming the gibraltar contract associated with Brexit is now removed....